Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/NYSE: AZN) supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzuma...
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene...
Thermo Fisher Scientific Inc, the world leader in serving science, announced the opening of a new, 70,000 sq.ft. distribution center in Bracetown, County...
Lonza Group AG, a world-leading contract development and manufacturing organisation (CDMO), has announced its decision to establish a new Global Capability...
Two Investment Zones designated in Scotland to establish UK-wide Investment Zones network. Investment Zones with designated tax sites offer tax benefits...
BioMed Realty, the largest private owner and operator of real estate for the life science, technology and innovation industries, announced that CordenPha...
FUJIFILM Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, &nb...
Acadia Pharmaceuticals Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the ...
Meiji Seika Pharma Co., Ltd. announced that morcamilast (proposed international nonproprietary name; development code: ME3183), a selective phosphodieste...
As artificial intelligence becomes increasingly embedded in formulation science and early clinical planning, the industry faces a dual challenge: accelerat...
New indications expand treatment options for appropriate children aged 2.5 years and older with Idiopathic Short Stature (ISS), born Small for Ges...
225Ac-PSMA-Trillium (BAY 3563254) is an investigational targeted alpha therapy (TAT) being developed for patients with advanced metastatic castration...
Charles River Laboratories has raised its 2026 profit forecast following a strategic divestiture of non-core and underperforming assets, ...
Priority Review Granted, Prescription Drug User Fee Act (PDUFA) Target Action Date Set for August 22, 2026 -- -- Company Plans to Submit the MOLBREEV...
© 2026 Biopharma Boardroom. All Rights Reserved.
